drugset / Trial / NCT06512194
Investigation to Understand and Optimize Psilocybin
Phase 2
Recruiting
141 enrolled
Charles Raison
Emory University · collabSteadman Philippon Research Institute · collabTiny Blue Dot Foundation · collabUsona Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.
Timeline
- Start
- 2025-05-13
- Primary completion
- 2029-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 25 mg | — |